|
|
Volumn 12, Issue 4, 2013, Pages 251-252
|
|
Molecular imaging as a de-risking tool: Coming into focus?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY CONJUGATE;
CARBON 11;
CARFENTANIL;
ETARFOLATIDE TC 99M;
FLORBETAPIR F 18;
FLUORODEOXYGLUCOSE;
FOLATE RECEPTOR;
GSK 1521498;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY B.72.3 IN 111;
MU OPIATE RECEPTOR AGONIST;
UNCLASSIFIED DRUG;
VINTAFOLIDE;
ZIRCONIUM;
ALZHEIMER DISEASE;
AMYLOID PLAQUE;
BLOOD BRAIN BARRIER;
DRUG APPROVAL;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG PENETRATION;
DRUG RESEARCH;
DRUG TARGETING;
FINANCIAL MANAGEMENT;
FUNCTIONAL MAGNETIC RESONANCE IMAGING;
HUMAN;
ISOTOPE LABELING;
MOLECULAR IMAGING;
NOTE;
OVARY CANCER;
OVERNUTRITION;
PATIENT SELECTION;
PHASE 2 CLINICAL TRIAL (TOPIC);
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
RISK REDUCTION;
TECHNOLOGY;
CENTRAL NERVOUS SYSTEM AGENTS;
CENTRAL NERVOUS SYSTEM DISEASES;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
MOLECULAR IMAGING;
TISSUE DISTRIBUTION;
|
|
EID: 84875697385
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3993 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
